Pulmonary lymphomatoid granulomatosis

Jump to navigation Jump to search

WikiDoc Resources for Pulmonary lymphomatoid granulomatosis

Articles

Most recent articles on Pulmonary lymphomatoid granulomatosis

Most cited articles on Pulmonary lymphomatoid granulomatosis

Review articles on Pulmonary lymphomatoid granulomatosis

Articles on Pulmonary lymphomatoid granulomatosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pulmonary lymphomatoid granulomatosis

Images of Pulmonary lymphomatoid granulomatosis

Photos of Pulmonary lymphomatoid granulomatosis

Podcasts & MP3s on Pulmonary lymphomatoid granulomatosis

Videos on Pulmonary lymphomatoid granulomatosis

Evidence Based Medicine

Cochrane Collaboration on Pulmonary lymphomatoid granulomatosis

Bandolier on Pulmonary lymphomatoid granulomatosis

TRIP on Pulmonary lymphomatoid granulomatosis

Clinical Trials

Ongoing Trials on Pulmonary lymphomatoid granulomatosis at Clinical Trials.gov

Trial results on Pulmonary lymphomatoid granulomatosis

Clinical Trials on Pulmonary lymphomatoid granulomatosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pulmonary lymphomatoid granulomatosis

NICE Guidance on Pulmonary lymphomatoid granulomatosis

NHS PRODIGY Guidance

FDA on Pulmonary lymphomatoid granulomatosis

CDC on Pulmonary lymphomatoid granulomatosis

Books

Books on Pulmonary lymphomatoid granulomatosis

News

Pulmonary lymphomatoid granulomatosis in the news

Be alerted to news on Pulmonary lymphomatoid granulomatosis

News trends on Pulmonary lymphomatoid granulomatosis

Commentary

Blogs on Pulmonary lymphomatoid granulomatosis

Definitions

Definitions of Pulmonary lymphomatoid granulomatosis

Patient Resources / Community

Patient resources on Pulmonary lymphomatoid granulomatosis

Discussion groups on Pulmonary lymphomatoid granulomatosis

Patient Handouts on Pulmonary lymphomatoid granulomatosis

Directions to Hospitals Treating Pulmonary lymphomatoid granulomatosis

Risk calculators and risk factors for Pulmonary lymphomatoid granulomatosis

Healthcare Provider Resources

Symptoms of Pulmonary lymphomatoid granulomatosis

Causes & Risk Factors for Pulmonary lymphomatoid granulomatosis

Diagnostic studies for Pulmonary lymphomatoid granulomatosis

Treatment of Pulmonary lymphomatoid granulomatosis

Continuing Medical Education (CME)

CME Programs on Pulmonary lymphomatoid granulomatosis

International

Pulmonary lymphomatoid granulomatosis en Espanol

Pulmonary lymphomatoid granulomatosis en Francais

Business

Pulmonary lymphomatoid granulomatosis in the Marketplace

Patents on Pulmonary lymphomatoid granulomatosis

Experimental / Informatics

List of terms related to Pulmonary lymphomatoid granulomatosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References